Department of Pathology and Laboratory Medicine, The University of Kansas Cancer Center, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
Neuro Oncol. 2013 Jun;15(6):691-706. doi: 10.1093/neuonc/not011. Epub 2013 Mar 12.
Glioblastoma multiforme is the most common form of primary brain tumor, often characterized by poor survival. Glioblastoma initiating cells (GICs) regulate self-renewal, differentiation, and tumor initiation properties and are involved in tumor growth, recurrence, and resistance to conventional treatments. The sonic hedgehog (SHH) signaling pathway is essential for normal development and embryonic morphogenesis. The objectives of this study were to examine the molecular mechanisms by which GIC characteristics are regulated by NPV-LDE-225 (Smoothened inhibitor; (2,2'-[[dihydro-2-(4-pyridinyl)-1,3(2H,4H)-pyrimidinediyl]bis(methylene)]bis[N,N-dimethylbenzenamine).
Cell viability and apoptosis were measured by XTT and annexin V-propidium iodide assay, respectively. Gli translocation and transcriptional activities were measured by immunofluorescence and luciferase assay, respectively. Gene and protein expressions were measured by quantitative real-time PCR and Western blot analyses, respectively.
NPV-LDE-225 inhibited cell viability, neurosphere formation, and Gli transcriptional activity and induced apoptosis by activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase. NPV-LDE-225 increased the expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-R1/DR4, TRAIL-R2/DR5, and Fas and decreased the expression of platelet derived growth factor receptor-α and Bcl2, and these effects were abrogated by Gli1 plus Gli2 short hairpin RNAs. NPV-LDE-225 enhanced the therapeutic potential of FasL and TRAIL by upregulating Fas and DR4/5, respectively. Interestingly, NPV-LDE-225 induced expression of programmed cell death 4 and apoptosis and inhibited cell viability by suppressing micro RNA (miR)-21. Furthermore, NPV-LDE-225 inhibited pluripotency-maintaining factors Nanog, Oct4, Sox2, and cMyc. The inhibition of Bmi1 by NPV-LDE-225 was regulated by induction of miR-128. Finally, NPV-LDE-225 suppressed epithelial-mesenchymal transition by upregulating E-cadherin and inhibiting N-cadherin, Snail, Slug, and Zeb1 through modulating the miR-200 family. Our data highlight the importance of the SHH pathway for self-renewal and early metastasis of GICs.
多形性胶质母细胞瘤是最常见的原发性脑肿瘤,通常生存预后较差。神经胶质瘤起始细胞(GICs)调节自我更新、分化和肿瘤起始特性,并参与肿瘤生长、复发和对常规治疗的抵抗。Hedgehog 信号通路对于正常发育和胚胎形态发生至关重要。本研究旨在探讨 NPV-LDE-225( smoothened 抑制剂;(2,2'-[[二氢-2-(4-吡啶基)-1,3(2H,4H)-嘧啶二基]双(亚甲基)]双[N,N-二甲基苯甲胺)调节 GIC 特征的分子机制。
通过 XTT 和 Annexin V-propidium iodide 测定分别测量细胞活力和细胞凋亡。通过免疫荧光和荧光素酶测定分别测量 Gli 易位和转录活性。通过定量实时 PCR 和 Western blot 分析分别测量基因和蛋白质表达。
NPV-LDE-225 通过激活 caspase-3 和切割多聚(ADP-核糖)聚合酶抑制细胞活力、神经球形成和 Gli 转录活性,并诱导细胞凋亡。NPV-LDE-225 增加肿瘤坏死因子相关凋亡诱导配体(TRAIL)-R1/DR4、TRAIL-R2/DR5 和 Fas 的表达,降低血小板衍生生长因子受体-α和 Bcl2 的表达,这些作用被 Gli1 和 Gli2 短发夹 RNA 阻断。NPV-LDE-225 通过上调 Fas 和 DR4/5 分别增强 FasL 和 TRAIL 的治疗潜力。有趣的是,NPV-LDE-225 通过抑制 microRNA(miR)-21 诱导程序性细胞死亡 4 和细胞凋亡并抑制细胞活力。此外,NPV-LDE-225 通过诱导 miR-128 抑制多能性维持因子 Nanog、Oct4、Sox2 和 cMyc。NPV-LDE-225 通过诱导 miR-128 抑制多能性维持因子 Nanog、Oct4、Sox2 和 cMyc。NPV-LDE-225 通过诱导 miR-128 抑制多能性维持因子 Nanog、Oct4、Sox2 和 cMyc。NPV-LDE-225 通过抑制 Bmi1 的表达。最后,NPV-LDE-225 通过上调 E-cadherin 和抑制 N-cadherin、Snail、Slug 和 Zeb1 抑制上皮-间充质转化,通过调节 miR-200 家族。我们的数据强调了 Hedgehog 通路对于 GIC 自我更新和早期转移的重要性。